The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of pembrolizumab plus paclitaxel with or without bevacizumab in PD-L1–positive recurrent triple-negative breast cancer previously treated with perioperative immune checkpoint inhibitors: WJOG16522B (PRELUDE) trial.
 
Kazuki Nozawa
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Lilly Japan
 
Yukinori Ozaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Lilly; Pfizer
 
Tomohiro Oshino
No Relationships to Disclose
 
Kaori Terata
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichikyo; Pfizer
 
Chikako Funasaka
Honoraria - Chugai Pharma; Daiichi Sankyo/Astra Zeneca (Inst); Eisai; Lilly; MSD
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst); Lilly Japan (Inst)
Other Relationship - Daiichi Sankyo/Astra Zeneca
 
Hitomi Sakai
No Relationships to Disclose
 
Manabu Futamura
No Relationships to Disclose
 
Chiyoe Kitagawa
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; MSD; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Abbvie; ALX Oncology; Daiichi Sankyo/Astra Zeneca; MSD; Ono Yakuhin; Sanofi
 
Tsutomu Iwasa
No Relationships to Disclose
 
Tatsuya Toyama
No Relationships to Disclose
 
Mikiya Ishihara
No Relationships to Disclose
 
Shinichiro Kashiwagi
No Relationships to Disclose
 
Koji Matsumoto
No Relationships to Disclose
 
Yuko Takahashi
Research Funding - MSD (Inst)
 
Satomi Watanabe
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; MSD K.K; Pfizer K.K.
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
 
Hideo Shigematsu
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Exact Sciences; Gilead Sciences; Kyowa Kirin International; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
 
Toshimi Takano
Honoraria - Daiichi Sankyo; Lilly